1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Onconic Therapeutics, Inc.

Onconic Therapeutics, Inc.

KKRX:476060
12,940.00
KRW
-130.00
(-0.99%)
536.45EPS
24.81P/E
603.74BMarket Cap
Nov 17Next Earn
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
26.2
41.09
910.47
453.72
1,214.37
1,836.63
Basic EPS, GAAP
-6,614
-6,242.25
72.75
-247.45
359
542.05
Free Cash Flow per Basic Share
-3,871.55
-7,585.97
128.97
-244.07
252.29
368.57
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
-738.39
-2,030.45
-1,822.45
5,185.03
1,620.79
1,910.96
Tangible Book Value per Share
-738.83
-2,030.79
-1,822.68
5,184.91
1,620.79
1,910.96
Basic Weighted Avg Shares
2
2
23
33
44
45
Sales/Revenue/Turnover
60
95
21,056
14,838
53,392
82,172
Operating Margin (%)
-13,903.24
-15,618.48
10.6
-32.33
23.63
21.06
Depreciation Expense
183
201
460
453
528
- -
Net Income, GAAP
-15,149
-14,432
1,682
-8,093
15,784
24,251
Effective Tax Rate (%)
- -
- -
- -
- -
- -
0.08
Profit Margin (%)
-25,247.72
-15,191.48
7.99
-54.54
29.56
29.51
Working Capital
18,520
1,581
-26,250
47,369
60,214
73,859
LT Debt
54
- -
199
120
45
84
Total Equity
-7,978
-21,937
-19,690
56,019
72,039
85,779
Return on Invested Capital (%)
- -
- -
- -
- -
- -
23.8
Return on Capital (%)
- -
- -
- -
- -
- -
33.4
Return on Common Equity (%)
- -
- -
- -
- -
24.65
33.51

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
81
58
187
LT Borrowings
- -
- -
- -
LT Finance Leases
45
57
84
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
45
45
Market Capitalization
868,940
944,889
603,741

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
63,837
75,764
80,967
Cash, Cash Equivalents & STI
52,735
57,305
62,616
Accounts Receivable, Net
10,531
17,863
17,387
Inventories
- -
- -
- -
Total Current Liabilities
3,623
7,992
7,108
Payables & Accruals
- -
- -
- -
ST Debt
81
58
187
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
28.6%
Free Cash Flow
- -
- -
-238.96%
Net Income, GAAP
- -
- -
-295.04%
Sales/Revenue/Turnover
- -
- -
259.82%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,320
2,695
1,987
8,837
14,838
2025
9,169
9,432
19,213
15,577
53,392
2026
22,982
24,399
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-132
-242
-392.75
130.25
-247.45
2025
10.75
-1
212.4
104.72
359
2026
143.12
83.12
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jon Kim
Full Time Employees
38
Sector
Health technology
Industry
Biotechnology
Address
11th Floor, Star Building, 12 Teheran-ro 26-gil, Gangnam-gu Seoul SL South Korea 06236
IPO Date
Dec 19, 2024
Website
onconic.co.kr
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Onconic Therapeutics Inc Onconic Therapeutics Inc. (476060.KQ) engages in the research, development, and commercialization of innovative biopharmaceuticals focused on cancer treatments, gastrointestinal disorders, and related therapies in South Korea. The company offers Zastaprazan (OCN-101, branded as Jaqbo or Zastaprazan citrate), a potassium-competitive acid blocker approved for erosive gastroesophageal reflux disease and gastric acid-related conditions; OCN-201 (JPI-547), an anticancer agent; JP-1366 (Nesuparib), a poly ADP-ribose polymerase and tankyrase inhibitor in phase 2 for pancreatic cancer, epithelial ovarian cancer, and other solid tumors including non-small cell lung cancer; and pipeline candidates targeting DNA damage response, immuno-oncology, peptic ulcers, and digestive diseases based on small molecules. Founded in 2020 and headquartered at 11F, 12 Teheranro-26-gil, Gangnam-gu, Seoul, South Korea, Onconic Therapeutics operates primarily in the biotechnology sector, serving global markets with high unmet medical needs through its emphasis on next-generation drugs expecting at least two approvals within three years; it functions as a subsidiary of Jeil Pharma Holdings. Recent developments include positive phase 3 results for Jaqbo (Zastaprazan) announced at Digestive Disease Week 2024, leading to regulatory approval by South Korea's Ministry of Food and Drug Safety as the country's 37th domestically developed new drug; a distribution partnership with Laboratorios Sanfer for Jaqbo launch across 19 Latin American countries; KOSDAQ listing in December 2024; and ongoing clinical advancements for Nesuparib in multiple oncology indications.